Light Sciences Oncology Doses First Patient With Aptocine

Light Sciences Oncology (LSO) has reported the treatment of the first patient in phase 1 pediatric study of its novel light-activated drug Aptocine (talaporfin sodium) in neurofibromatosis type 1 (NF-1).

Reportedly, the goal of the study is to enroll 18-24 patients between 3 and 21 years of age with debilitating, severely disfiguring, life-threatening, or progressive PN tumors that are not surgically resectable, and for which no other standard medical management exists.

Llew Keltner, president and CEO of LSO, said: A clinical trial in neurofibromatosis is an exciting step forward in the development of Aptocine for patients with a significant unmet medical need outside our primary cancer focus. I am proud and delighted that LSO is now associated with developing a treatment of this condition in children and adults.